Cargando…
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associ...
Autores principales: | Rimm, David L., Han, Gang, Taube, Janis M., Yi, Eunhee S., Bridge, Julia A., Flieder, Douglas B., Homer, Robert, Roden, Anja C., Hirsch, Fred R., Wistuba, Ignacio I., Pusztai, Lajos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567382/ https://www.ncbi.nlm.nih.gov/pubmed/31196152 http://dx.doi.org/10.1186/s13058-019-1156-6 |
Ejemplares similares
-
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020) -
CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022) -
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017) -
Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017) -
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)